Integrating Cost into Shared Decision-Making for Heart Failure with Reduced Ejection Fraction (POCKET-COST-HF): A Trial Providing Out-of-Pocket Costs for Heart Failure Medications during Clinical Encounters - 13/02/24
, Birju R. Rao, MD a, #, Andrea R. Mitchell, MPH a, Candace D. Speight, MPH a, Larry A. Allen, MD, MHS b, Scott D. Halpern, MD, PhD c, Yi-An Ko, PhD d, Daniel D. Matlock, MD, MPH b, Miranda A. Moore, PhD e, Alanna A. Morris, MD, MSc a, Laura D. Scherer, PhD b, Peter Ubel, MD f, Neal W. Dickert, MD, PhD a, gABSTRACT |
Background |
Evidence-based medical therapy for heart failure with reduced ejection fraction (HFrEF) often entails substantial out-of-pocket costs that can vary appreciably between patients. This has raised concerns regarding financial toxicity, equity, and adherence to medical therapy. In spite of these concerns, cost discussions in the HFrEF population appear to be rare, partly because out-of-pocket costs are generally unavailable during clinical encounters. In this trial, out-of-pocket cost information is given to patients and clinicians during outpatient encounters with the aim to assess the impact of providing this information on medication discussions and decisions.
Hypothesis |
Cost-informed decision-making will be facilitated by providing access to patient-specific out-of-pocket cost estimates at the time of clinical encounter.
Design |
Integrating Cost into Shared Decision-Making for Heart Failure with Reduced Ejection Fraction (POCKET-COST-HF) is a multicenter trial based at Emory Healthcare and University of Colorado Health. Adapting an existing patient activation tool from the EPIC-HF trial, patients and clinicians are presented a checklist with medications approved for treatment of HFrEF with or without patient-specific out-of-pocket costs (obtained from a financial navigation firm). Clinical encounters are audio-recorded, and patients are surveyed about their experience. The trial utilizes a stepped-wedge cluster randomized design, allowing for each site to enroll control and intervention group patients while minimizing contamination of the control arm.
Discussion |
This trial will elucidate the potential impact of robust cost disclosure efforts and key information regarding patient and clinician perspectives related to cost and cost communication. It also will reveal important challenges associated with providing out-of-pocket costs for medications during clinical encounters. Acquiring medication costs for this trial requires an involved process and outsourcing of work. In addition, costs may change throughout the year, raising questions regarding what specific information is most valuable. These data will represent an important step towards understanding the role of integrating cost discussions into heart failure care.
ClinicalTrials.gov identifier |
NCT04793880.
Le texte complet de cet article est disponible en PDF.Plan
Vol 269
P. 84-93 - mars 2024 Retour au numéro
Article précédent
- Study design and rationale of COMPETE: Comparison of the effect of medication therapy in alleviating migraine with patent foramen ovale
- Ziping Li, Jie Dong, Yiming Yan, Fang Fang, Chuangshi Wang, Fengwen Zhang, Wenbin Ouyang, Shouzheng Wang, Xiangbin Pan
- Effects of trimetazidine on cardiac function in adult cyanotic congenital heart disease patients: Protocol for a 3-month multicenter, randomized, double-blind controlled trial
- Yi Shen, Li Xiang, Yifan Zhu, Chenyu Jiang, Xingliang Zhou, Xu Huang, Liwei Wu, Bei Feng, Yi Yan, Yiwei Liu, Hao Zhang
Bienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.
Déjà abonné à cette revue ?